[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption] ? New clinical alliance with GenesisCare to offer combined therapy of Veyonda? and 177Lu-PSMA 177Lu-PSMA is used as a treatment for late stage prostate cancer patients ? Both agents to be offered in a compassionate use program in Australia ? Combination therapy may be beneficial in boosting the response to 177Lu-PSMA Sydney, 18th February 2020: Noxopharm (ASX: NOX) is pleased to announce a clinical alliancewith oncology services provider GenesisCare to offer a compassionate access program with Noxopharm?s novel lead product candidate, Veyonda?, for patients with advanced, treatmentresistant, metastatic prostate cancer (mCRPC) being treated with theranostics. The alliance formalises a program under which Noxopharm has been making Veyonda? available through GenesisCare for compassionate use in combination with 177Lu-PSMA therapy for mCRPC patients in?Australia. Following promising clinical outcomesfrom the compassionate use program and early clinical research, the two companies have formalised an arrangement to make the therapy available for use in patients with few treatment alternatives. GenesisCare is one of the largest private providers of oncology services in Australia and Europe, offering a range of treatments including radiation therapy, chemotherapy, palliative radiation and nuclear medicine (theranostics). Professor Nat Lenzo, Clinical Director of Theranostics at GenesisCare and Clinical Professor at Curtin University said: ?Prostate cancer is the most common cancer among men in Australia, yet treatment options for advanced metastatic prostate cancer remain limited. Theranostics is offering new hope for late stage prostate cancer patients, many of whom have exhausted conventional treatment options such as chemotherapy. While further studies are required, we are seeing encouraging results from the combination of Lu-PSMA and Veyonda? in select patients requiring additional treatment effects and are grateful for Noxopharm?s support to increase access to this combined therapy for suitable patients.? Noxopharm Limited: ABN 50 608 966 123 Suite 3, Level 4, 828 Pacific Highway, Gordon NSW 207 Noxopharm Limited: ABN 50 608 966 123 Suite 3, Level 4, 828 Pacific Highway, Gordon NSW 2072 AUSTRALIA About 177Lu-PSMA PSMA is a protein (prostate surface membrane antigen) expressed on prostate cancer cells in about 85-90% of men with mCRPC. In management of advanced prostate cancer, prostate specific membrane antigen (PSMA)-based compounds (ligands), 68Gallium PSMA and 177Lutetium PSMA, are the most commonly used 'theranostic pair' for detection and treatment of metastatic disease respectively. The PSMA protein is over-expressed on prostate cancer cells and has been the subject of numerous studies highlighting its suitability as a diagnostic and therapeutic agent. 177Lutetium is a radioisotope used in prostate cancer due its physical properties which facilitate tumour tissue death while avoiding unwanted effects on healthy tissue. About Veyonda? Veyonda? is a suppository dosage form of idronoxil, a first-in-class inhibitor of sphingosine-1- phosphate (S1P). S1P is a key secondary messenger in cells, with dual roles of activating major pro-survival signalling pathways, and regulating immune cell trafficking in tissues. Many solid cancers over-express S1P, supporting unregulated tumour growth and suppressing immune cell populations and activities in tumours. By inhibiting this over-expression, idronoxil acts as both a radio-sensitiser and chemo-sensitiser, and as an immunotherapy, intended to restore immune function to tumours. About the Compassionate Use Program In Australia, access to emerging theranostics treatment such as 177Lu-PSMA and Veyonda? are via active clinical trials or with authorisation by the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS), a scheme for compassionate access to medicines prior to their registration. About Noxopharm Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda? and is the major shareholder in non-oncology drug development company, Nyrada Inc. (ASX:NYR) www.noxopharm.com Investor & Corporate Enquiries: Company Secretary: Prue Kelly David Franks M: 0459 022 445 T: +61 2 8072 1400 E: info@noxopharm.com E: David.Franks@automicgroup.com.au Media queries: Catherine Strong Citadel-MAGNUS T: 02 8234 0111 E: cstrong@citadelmagnus.com Noxopharm Limited: ABN 50 608 966 123 Suite 3, Level 4, 828 Pacific Highway, Gordon NSW 2072 AUSTRALIA About GenesisCare GenesisCare is one of the largest private providers of oncology and cardiology services in Australia, the U.K. and Spain with 3,000 healthcare professionals and support staff across more than 150 GenesisCare centres. GenesisCare sees 160,000 people annually and carries out more than 350,000 radiation therapy treatments every year, along with treatment options including chemotherapy and theranostics. The organisation expects to more than double its reach in 2020, with the acquisition of a major U.S. oncology provider under way. www.genesiscare.com The GenesisCare theranostics team is committed to developing and using targeted molecular diagnostic imaging and therapeutic agents for the diagnosis and treatment of cancers, with a focus on cancers which are difficult to treat. For details on available locations visit genesiscare.com/au/theranostics/ GenesisCare Clinical Media Enquiries: GenesisCare Corporate Media Enquiries: Bronte Kerr Lauren Coleman M: +61 428 298 121 T: +61 413 254 545 E: Bronte.Kerr@genesiscare.com E: Lauren.Coleman@genesiscare.com Graham Kelly, CEO and Chairman of Noxopharm has approved the release of this document to the market. Forward Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as ?aim?, ?anticipate?, ?assume?, ?believe?, ?continue?, ?could?, ?estimate?, ?expect?, ?intend?, ?may?, ?plan?, ?predict?, ?project?, ?plan?, ?should?, ?target?, ?will? or ?would? or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company?s control that could cause the actual results,